Archive | Biotech Patents RSS feed for this section

Update on natural products doctrine in the wake of Myriad

In our previous note, we had taken a rather optimistic view of the post-Myriad patentability of patents directed towards purified non-genomic DNA biological products, such as, for example, stem cells, peptides, antibodies, industrial enzymes, vaccines and diagnostic assays, among others.   We had hoped that the courts and the USPTO would not extend the Myriad ruling […]

Comments Off on Update on natural products doctrine in the wake of Myriad Continue Reading →

Patentable claim types after Myriad

By David Mellman, Ph.D and Mary Breen Smith Note: please see update (published June 4, 2014) with regards to this issue. In June 2013, the U.S. Supreme Court held in Association for Molecular Pathology vs.  Myriad Genetics, Inc., No. 12-398 (569 U.S. ___ June 13, 2013) that isolated genomic DNA sequences that are identical to […]

Comments Off on Patentable claim types after Myriad Continue Reading →

What makes a diagnostics-type claim patentable after Prometheus?

“Personalized medicine” is of increasing importance in the medical field today.  Personalized medicine, broadly speaking, refers to the design of medical treatments for the individual characteristics of each patient.  As of March 2013, there were approximately 119 drugs approved by the U.S. Food and Drug Administration (FDA) with pharmacogenomics markers in their labels.  Scientific research […]

Comments Off on What makes a diagnostics-type claim patentable after Prometheus? Continue Reading →

Myriad Genetics Supreme Court decision, June 13, 2013

Assoc. for Molecular Path. et al. v. Myriad Genetics, Inc., No. 12-398 (U.S., June 13, 2013). The Supreme Court decided today that “[a] naturally occurring DNA segment is a product of nature and not patent eligible merely because it has been isolated” under 35 U.S.C. Section 101.  Therefore, naturally occurring DNA sequences containing both intron and […]

Comments Off on Myriad Genetics Supreme Court decision, June 13, 2013 Continue Reading →

How Far Does the Monopoly Conferred by a Patent Extend?

By: Tony Sanny, Ph.D In the recent U.S. Supreme Court decision, Bowman v. Monsanto Co., U.S., No. 11-796, 5/13/2013, the Court held that the patent monopoly does extend to later generations of self-replicating seeds.  Yet, the Bowman decision left open important questions regarding how far the monopoly rights conferred by a patent extend.  The Court […]

Comments Off on How Far Does the Monopoly Conferred by a Patent Extend? Continue Reading →

The Q Factor: In the News

Patent Ratings annual take on who prosecutes the highest-quality patents. Swanson & Bratschun, LLC received top honors in the Biotech category. View the complete article as a PDF.

Comments Off on The Q Factor: In the News Continue Reading →